Fig. 6: GP73 blockade inhibits SARS-CoV-2-induced gluconeogenesis enhancement.
From: GP73 is a glucogenic hormone contributing to SARS-CoV-2-induced hyperglycemia
a–d, Plasma GP73 levels (a) or glucose levels (c) in healthy controls and patients with COVID-19. P < 0.0001 for COVID-19 versus healthy by two-tailed Student’s t-tests (a,c). Plasma GP73 levels (b) or blood glucose levels (d) in healthy controls and patients with COVID-19 with different disease severities. P = 0.0198 for moderate versus healthy (b) and P < 0.0001 for severe versus healthy (b), P = 0.0193 for moderate versus healthy (d) and P < 0.0001 for severe versus healthy (d) by one-way ANOVA followed by Bonferroni’s post hoc test. e, Correlation analysis between plasma GP73 levels and glucose levels in patients with COVID-19. P < 0.0001 by Pearson correlation analysis. f,g, Glucose levels (f) or plasma GP73 levels (g) in patients with COVID-19 at admission, inpatient and after recovery. In the box-and-whisker plots, the box represents the upper and lower quartiles and the line within the box is the mean. The whiskers represent the maximum and minimum values. P < 0.0001 for admission versus healthy, inpatient versus healthy and recovery versus healthy (f,g) by one-way ANOVA followed by Bonferroni’s post hoc test. Data are mean ± s.e.m. *P < 0.05; ***P < 0.001.
